22nd Century Group, Inc. (NYSE MKT:XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that the journal Nicotine and Tobacco Research has published a new study showing how 22nd Century's Very Low Nicotine (VLN) cigarettes can be part of an effective tobacco control strategy for forward-looking countries like New Zealand. The study concluded that reducing the price of VLN cigarettes compared to regular cigarettes will reduce nicotine dependence and improve health and financial outcomes for smokers. The New Zealand Government is committed to achieving its "Smokefree 2025" goal, which aims to reduce smoking pre... [Read more]